



FDA Adverse Events Reports (FAERS) Summary for TRIPTORELIN

These tables and charts are based on 3,851 total reports for TRIPTORELIN (TRIPTORELIN) received by the FDA Adverse Event Reporting System (FAERS) from 2004 through April 28, 2026.

This FAERS total includes 3,836 **pharmaceutical company-submitted and non-U.S.** FAERS reports and 15 **U.S. consumer or healthcare provider-submitted** MedWatch reports. For a separate summary of the 15 U.S. reports filed via the **FDA MedWatch** voluntary reporting system, view our **FDA MedWatch TRIPTORELIN** summary report. (See notes section below for explanation of FDA's mandatory and voluntary reporting system.)

Top 20 Adverse Effects Associated with TRIPTORELIN (reported in FAERS Database)


	Side Effect	# of FDA Reports
1	DEATH	320
2	OFF LABEL USE	318
3	OVARIAN HYPERSTIMULATION SYNDROME	250
4	DISEASE PROGRESSION	195
5	CANCER PROGRESSION	122
6	LACK OF STRENGTH AND ENERGY (ASTHENIA)	110
7	DEMENTIA ALZHEIMER’S TYPE	106
8	ANAEMIA	105
9	FATIGUE	101
10	HOT FLUSH	98
11	NAUSEA	98
12	FEVER	96
13	SHORTNESS OF BREATH	94
14	VOMITING	93
15	DRUG INEFFECTIVE	91
16	HEADACHE	89
17	ACUTE KIDNEY INJURY	84
18	ABDOMINAL PAIN	80
19	DRUG INTERACTION	76
20	TERMINAL STATE	76

Show More Reactions (20)


Latest Known Outcomes for Reactions Reported for TRIPTORELIN

	Latest Known Outcome for Reported Reactions	Number of Cases
1	Unknown Outcome	2013
2	Patient recovered	1018
3	Patient has not recovered/symtoms have not resolved	639
4	Patient died	526
5	Patient is recovering/symptoms resolving	400
6	Patient has recovered but has consequent health issues	79

Number of FAERS Reports by Year for TRIPTORELIN



Number of FAERS Reports by Patient Age for TRIPTORELIN



Search all MedWatch and FAERS by keyword:



QUIZ

98% Of Adults Fail This Quiz

Just TRY and get higher than 25%

Heywise

Open >



TRIPTORELIN Total Reports

Male	Female	Unknown	Total
2115	1500	236	3,851

Top Countries Reporting

Country	Number of Reports
1 United States	590
2 France	459
3 EU	402
4 Netherlands	401
5 Italy	297
6 Germany	206
7 United Kingdom	191
8 China	163
9 Spain	154
10 Canada	113

Outcomes for Reports

Serious: 3323

Not Serious: 527

Note: A serious outcome means the adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition.

Top Indications

Breast cancer

Top Companies Reporting

VERITY PHARMACEUTICALS INC.
AZURITY PHARMACEUTICALS
VERITY PHARMACEUTICALS
VERITY PHARMACEUTICALS INC.

Safety-Related FDA Updates

TRIPTODUR KIT (TRIPTORELIN PAMOATE)

Rx Drug:

[Safety-related Labeling Changes](#)

Have experience (good or bad) with TRIPTODUR KIT? Rate TRIPTODUR KIT at Ask a Patient.

For serious adverse events, report them to the FDA by contacting the drug manufacturer or report directly through the [MedWatch voluntary reporting form](#).

Notes

This report, created by AskaPatient.com, is derived from the cases for TRIPTORELIN reported to the **United States Food and Drug Administration** (FDA) FDA Safety Information and Adverse Event Reporting System (**FAERS**) and obtained from [Open FDA](#). Data was last updated with reports received through April 28, 2026.

This summary includes ALL reports where the drug is a "primary OR secondary OR suspected interacting" drug. Typically, reports are filed for the most serious type or "event" and do not represent incidental or minor side effects. The majority of these reports are mandatory reports submitted by pharmaceutical companies, who receive complaints from consumers. The reactions, side effects, or "adverse events," represent up to the 20 most frequently occurring events in the database for a drug related to the event. This report also features counts of latest known outcomes associated with reported side effects, but does not provide the specific outcomes for specific adverse events.

Adverse Event Reports are submitted to the FAERS database by pharmaceutical companies (**mandatory reporting** is required by manufacturers, distributors, or importers). [Health](#) care providers such as doctors (**voluntary reporting**), and patients themselves (**voluntary reporting**) report to the FDA directly through the MedWatch program. Those MedWatch reports are coded and included in the FAERS database. This report mainly consists of the mandatory reports, because the MedWatch reports are a small percentage (3 - 5%) of total reports. Link to the MedWatch summary report at the top of the page for a summary of the **directly reported (voluntary)** adverse events for this drug. The number of reports included here might differ somewhat from the number of reports in the downloadable quarterly FAERS reports and in the online FAERS dashboard, due to lags in reporting, drug name differences, duplicates, and other factors. Open FDA states that it only includes the most recent version of a case report. It also adds the disclaimer: "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated."

Discover related topics

Drug of Choice for Precocious Puberty >

Patient Safety Medical Devices >

Improve Safety of Medical Devices >

Diphereline 11.25 Mg Price >

Cosmetics and the Fda >

FDA uses the "MedDRA" classification system to describe reported adverse reactions. [MedDRA](#) is a standardized medical terminology that facilitates sharing of regulatory information internationally. In some cases, "patient friendly" terms for the layman designated by MedDRA have been substituted for medical jargon. Please [contact us](#) with questions or comments about this report.

Subscribe to Ask a Patient® Health News:

Enter email address

Subscribe